A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis
A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis
复制标题
DOI：
10.1016/j.nut.2008.11.017
复制
发表时间：
2009-05-01
期刊：
影响因子：
4.4
通讯作者：
Sakamoto, Choitsu
中科院分区：
文献类型：
--
作者：
Fujimori, Shunji;Gudis, Katya;Sakamoto, Choitsu
目的：研究表明，合生素治疗可以证明在治疗溃疡性结肠炎（UC）比治疗局限于益生菌或益生元更有效。本研究比较了这些疗法在治疗UC.Methods的效果：120例UC门诊患者随机分为三组，每组40例，分别为益生菌，益生元，合生素治疗。益生菌组每天摄入一粒由长双歧杆菌2 × 10（9）菌落形成单位组成的胶囊，益生元组每天摄入8.0 g剂量的车前子。合生元组接受两种治疗。所有患者在试验开始时、试验2周中点和试验4周结束时完成炎症性肠病问卷（IBDQ）。血液变量也进行了评估，在一个子集的32例随机选择的所有组和值进行了比较与IBDQ scores.Results：31例患者在益生菌组，31在益生元组，32在合生元组合格的分析。其余26例患者的问卷不完整。试验结束时，各组的IBDQ总评分均有所改善（益生菌162至169，NS;益生元174至182，NS;合生元168至176，P = 0.03）。个体评分改善如下：益生菌，情绪功能（P = 0.03）;益生元，肠功能（P = 0.04）;合生元，全身和社会功能（P = 0.008和P = 0.02）。C反应蛋白仅在合生素治疗后显着下降（从0.59降至0.14 mg/dL，P = 0.04）。没有不良事件。结论：与益生菌或益生元治疗的患者相比，合生元治疗的UC患者经历了更大的生活质量变化。这些数据表明合生素治疗在UC的治疗中可能具有协同作用。(C)2009年由Elsevier Inc.出版
Objective: Studies suggest that synbiotic therapy could prove more effective in the treatment of ulcerative colitis (UC) than therapies limited to probiotics or prebiotics. This study compared the effect of each of these therapies in the treatment of UC.Methods: One hundred twenty outpatients with UC were randomly sorted into three groups of 40 patients each for probiotic, prebiotic, or synbiotic therapy. The probiotic group ingested one daily capsule consisting of Bifidobacterium longum 2 X 10(9) colony-forming units and the prebiotic group ingested daily 8.0-g doses of psyllium. The synbiotic group underwent both treatments. All patients completed Inflammatory Bowel Disease Questionnaires (IBDQs) at the onset of the trial, at the 2-wk midpoint, and at the 4-wk end of the trial. Blood variables were also evaluated in a subset of 32 patients randomly selected from all groups and values were compared with IBDQ scores.Results: Thirty-one patients in the probiotic group, 31 in the prebiotic group, and 32 in the synbiotic group qualified for analyses. The remaining 26 patients had incomplete questionnaires. Total IBDQ scores improved within groups by the end of the trial (probiotics 162 to 169, NS; prebiotics 174 to 182, NS; synbiotics 168 to 176, P = 0.03). Individual scores improved as follows: probiotics, emotional function (P = 0.03); prebiotics, bowel function (P = 0.04); and synbiotics, systemic and social functions (P = 0.008 and P = 0.02). C-reactive protein decreased significantly only with synbiotic therapy (from 0.59 to 0.14 mg/dL, P = 0.04). There were no adverse events.Conclusion: Patients with UC on synbiotic therapy experienced greater quality-of-life changes than patients on probiotic or prebiotic treatment. These data suggest that synbiotic therapy may have a synergistic effect in the treatment of UC. (C) 2009 Published by Elsevier Inc.